Related Experiment Video
Updated: Aug 14, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT
1Dept. of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Haematologica
|June 21, 2006
Abstract:
Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation.
